PD-1 targeted IL-15/IL-15Rα Fc fusion proteins with improved properties
US11932675B2 · kind B2 · utility
0Cited by
42References
15Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Oct 9, 2020 |
| Grant date | Mar 19, 2024 |
| Priority date | — |
| Expiry date | Jan 19, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to fusion proteins comprising variant IL-15 proteins, fusion proteins comprising variant anti-PD-1 antigen binding domains, and fusion proteins comprising variant IL-15 proteins and variant anti-PD-1 antigen binding domains. The present invention also relates to nucleic acid molecules, expression vectors, host cells and methods for making such fusion proteins and the use of such fusion proteins in the treatment of cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.